TAO Synergies (TAOX) Non-Current Assets (2019 - 2026)
TAO Synergies' (TAOX) quarterly Non-Current Assets came in at $486582.0 in Q2 2026, up 4358.33% on a YoY basis from $10914.0 in Q2 2025, and down 39.64% quarter-over-quarter from $806187.0 in Q1 2026.
Analysis
TAO Synergies (TAOX) Non-Current Assets (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Non-Current Assets for 8 consecutive years, with $486582.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Assets rose 4358.33% year-over-year to $486582.0; the trailing twelve-month figure through Jun 2026 stood at $1.8 million (up 202.38% YoY), and the FY2025 full-year result was $456263.0, up 3430.08% from the prior year.
- Non-Current Assets eased to $486582.0 in Q2 2026 per TAOX's latest filing, from $806187.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $806187.0 in Q1 2026 and bottomed at $10111.0 in Q3 2025.
- Historically, Non-Current Assets has averaged $233315.8 across 5 years, with a median of $21838.5 in 2022.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets plunged 98.15% in 2025, then soared 6678.67% in 2026.
- Over 5 years, Non-Current Assets stood at $22145.0 in 2022, then surged by 2523.2% to $580907.0 in 2023, then slumped by 97.78% to $12925.0 in 2024, then jumped by 3430.08% to $456263.0 in 2025, then increased by 6.65% to $486582.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $486582.0, $806187.0, and $456263.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | 564.41 Mn |
| 10 | TAO Synergies | 30.86 Mn | 30.86 Mn | - | 486,582.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 486,582.00 |
| Mar 31, 2026 | 806,187.00 |
| Dec 31, 2025 | 456,263.00 |
| Sep 30, 2025 | 10,111.00 |
| Jun 30, 2025 | 10,914.00 |
| Mar 31, 2025 | 11,893.00 |
| Dec 31, 2024 | 12,925.00 |
| Sep 30, 2024 | 546,027.00 |
| Jun 30, 2024 | 559,741.00 |
| Mar 31, 2024 | 570,908.00 |
| Dec 31, 2023 | 580,907.00 |
| Sep 30, 2023 | 19,715.00 |
| Jun 30, 2023 | 21,438.00 |
| Mar 31, 2023 | 22,493.00 |
| Dec 31, 2022 | 22,145.00 |
| Sep 30, 2022 | 21,532.00 |
| Jun 30, 2022 | 20,777.00 |
| Mar 31, 2022 | 19,126.00 |
| Dec 31, 2021 | 20,445.00 |
| Sep 30, 2021 | 18,485.00 |